{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059322","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.360009+00:00","generated_at":"2026-06-02T05:22:54.724044+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Iovance reports Q1 net loss $113M; Amtagvi launch strong with 100+ patients enrolled across 40+ ATCs","bullets":["Net loss $113.0M ($0.42 per share) vs $107.4M ($0.50) YoY; revenue $0.7M from Proleukin sales.","Cash, equivalents & investments $362.6M vs $346.3M at Dec 31, 2023; runway into H2 2025.","More than 100 patients enrolled for Amtagvi since Feb 16 FDA approval; ~50 ATCs on track by end of May, 70+ by year-end.","Manufacturing turnaround ~34 days; >75% of enrolled patients covered by private payers.","Regulatory filings for lifileucel on track in EU (Q2 2024), UK/Canada (H2 2024), Australia (2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059322","json":"https://secwatch.observer/filing/0001104659-24-059322.json","markdown":"https://secwatch.observer/filing/0001104659-24-059322.md","text":"https://secwatch.observer/filing/0001104659-24-059322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924059322/0001104659-24-059322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924059322/tm2413980d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:22:54.724044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b31708d2e725a943aa4b4e4a7f9d8153e88c23ca","claim":"IOVANCE BIOTHERAPEUTICS, INC. reported financial results for first quarter 2024.","evidence_excerpt":"On May 9, 2024, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924059322/0001104659-24-059322-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}